Skip to main content

M Mar Mañu Pereira

Head of research Lab in rare anemia disorders - Senior researcher Scientific Director of ERN-EuroBloodNet Coordinator of the European platforms for patients registries in hematology ENROL and in rare anemia disorders RADeep

Institutions of which they are part

Main researcher
Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca

M Mar Mañu Pereira

Institutions of which they are part

Main researcher
Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca

Head of research Lab in rare anemia disorders - Senior researcher Scientific Director of ERN-EuroBloodNet Coordinator of the European platforms for patients registries in hematology ENROL and in rare anemia disorders RADeep

Head of research Lab in rare anemia disorders at VHIR - 2018 - Currently
Institut de Recerca contra la Leucèmia Josep Carreras - 2016-2018
Institut d'Investigacions Biomèdiques August Pi i Sunyer / Hospital Clínic de Barcelona - 2002-2016
Dr in BioMedicine 2009

Projects

Erythrocytes properties and viability in dependence of flow and extra-cellular environment (EVIDENCE)

IP: M Mar Mañu Pereira
Collaborators: Amira Idrizovic
Funding agency: EUROPEAN COMMISSION
Funding: 250904.88
Reference: EVIDENCE_H2020_MSCA-ITN2019
Duration: 01/01/2020 - 31/12/2023

European Rare Blood Disorders Platform - ENROL

IP: M Mar Mañu Pereira
Collaborators: Claire Diot
Funding agency: EUROPEAN COMMISSION
Funding: 93954.6
Reference: ENROL_HP-PJ-01-2019
Duration: 01/06/2020 - 31/05/2023

European Reference Network on Rare Hematological Diseases [ERN-EuroBloodNet] [739541] - Framework Partnership Agreement

IP: M Mar Mañu Pereira
Collaborators: Victoria Gutierrez Valle, Reidel , Sara Isabel, Sara Isabel Reidel
Funding agency: EUROPEAN COMMISSION
Funding: 545439.59
Reference: EUROBLOODNET_FPA-ERN3HP2016
Duration: 01/03/2018 - 30/04/2022

Related news

The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.

A study jointly led by the Hospital Clínic of Barcelona and the Vall d'Hebron Research Institute (VHIR) confirms the effectiveness of neonatal screening in reducing morbidity among children with sickle cell disease (SCD).

Active participation by patients and families in studies helps identify more effective therapies that improve quality of life and survival.

Related professionals

Ingrid Galán Cartaña

Ingrid Galán Cartaña

Senior researcher
Clinical Neuroimmunology
Read more
Masotto , Barbara

Masotto , Barbara

Predoctoral researcher
Genetics Medicine
Read more
Mercedes Martinez Mansilla

Mercedes Martinez Mansilla

Research technician
Translational Molecular Pathology
Read more
Ulloa Navas, Ana Daniela

Ulloa Navas, Ana Daniela

Rheumatology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.